Development Highlights – During the reporting Period, four of the Group’s innovative products were approved for marketing by the National Medical Products Administration of China …
中国生物制药（1177.HK）公布2024中期业绩
重点成果 – 期内，集团共有4个创新产品获中国国家药品监督管理局（「NMPA」）批准上市，分别为安得卫（贝莫苏拜单抗注射液）、安柏尼（富马酸安奈克替尼胶囊）、安洛晴（枸橼酸依奉阿克胶囊）和贝乐林（利拉鲁肽注射液），其中3个为国家…